These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26099427)

  • 41. DEX implant intravitreal injection, sustained intraocular hypertension, and steroid-induced glaucoma in patients with no risk factors.
    Rezkallah A; Kodjikian L; Malclès A; Dot C
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):219-220. PubMed ID: 28801709
    [No Abstract]   [Full Text] [Related]  

  • 42. Association of OCT angle recess width with IOP response after intravitreal triamcinolone injection.
    Singer MA; Groth SL; Sponsel WE; Herro A; Pollard J; Cohen SR; Cohen JH
    Retina; 2013 Feb; 33(2):282-6. PubMed ID: 22846803
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Laser trabeculoplasty.
    Lau LI; Liu CJ; Chen SJ; Ko YC; Lee FL; Hsu WM
    Ophthalmology; 2007 Sep; 114(9):1790. PubMed ID: 17822985
    [No Abstract]   [Full Text] [Related]  

  • 44. OBSERVED COMPLICATIONS FROM DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR EDEMA IN RETINAL VEIN OCCLUSION OVER 3 TREATMENT ROUNDS.
    Reid GA; Sahota DS; Sarhan M
    Retina; 2015 Aug; 35(8):1647-55. PubMed ID: 25932545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of intravitreal triamcinolone acetonide injection with and without preservative.
    Maia M; Farah ME; Belfort RN; Penha FM; Lima Filho AA; Aggio FB; Belfort R
    Br J Ophthalmol; 2007 Sep; 91(9):1122-4. PubMed ID: 17383993
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging drugs for diabetic retinopathy.
    Pipis A; Scholl S; Augustin AJ
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):669-81. PubMed ID: 22112046
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.
    Adelman RA; Zheng Q; Mayer HR
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):105-10. PubMed ID: 20187807
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors.
    Vasconcelos-Santos DV; Nehemy PG; Schachat AP; Nehemy MB
    Retina; 2008 Apr; 28(4):573-80. PubMed ID: 18398360
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predicting the safety zone for steroid-induced ocular hypertension induced by intravitreal dexamethasone implantation.
    Choi W; Bae HW; Shin HJ; Kim EW; Kim CY; Kim M; Seong GJ
    Br J Ophthalmol; 2022 Aug; 106(8):1150-1156. PubMed ID: 33737305
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Intraocular pressure elevation after subtenon injection of triamcinolone acetonide during uveitis].
    Bui Quoc E; Bodaghi B; Adam R; Burtin T; Cassoux N; Dreifuss S; Fardeau C; LeHoang P
    J Fr Ophtalmol; 2002 Dec; 25(10):1048-56. PubMed ID: 12527830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Short-term complications of intravitreal injection of triamcinolone acetonide.
    Roth DB; Realini T; Feuer WJ; Radhakrishnan R; Gloth J; Heimmel MR; Fechtner RD; Yarian DL; Green SN
    Retina; 2008 Jan; 28(1):66-70. PubMed ID: 18185140
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dexamethasone for ocular inflammation.
    Saraiya NV; Goldstein DA
    Expert Opin Pharmacother; 2011 May; 12(7):1127-31. PubMed ID: 21457057
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and efficacy of intraoperative intravitreal injection of triamcinolone acetonide injection after phacoemulsification in cases of uveitic cataract.
    Dada T; Dhawan M; Garg S; Nair S; Mandal S
    J Cataract Refract Surg; 2007 Sep; 33(9):1613-8. PubMed ID: 17720079
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intraocular corticosteroids for posterior segment disease: 2012 update.
    Kiernan DF; Mieler WF
    Expert Opin Pharmacother; 2012 Aug; 13(12):1679-94. PubMed ID: 22783878
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation.
    Sadiq MA; Agarwal A; Soliman MK; Hanout M; Sarwar S; Do DV; Nguyen QD
    Expert Opin Drug Saf; 2015 Jul; 14(7):1147-56. PubMed ID: 25994877
    [TBL] [Abstract][Full Text] [Related]  

  • 57. INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Storey PP; Ho V; Yeh S; Reddy S; Fang-Yen NH; Pequignot E; Leiby BE; Fineman M; Garg S; Hubbard GB; Hsu J
    Retina; 2015 Oct; 35(10):1992-2000. PubMed ID: 26035396
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment of oedematous, proliferative and neovascular diseases by intravitreal triamcinolone acetonide].
    Jonas JB; Kreissig I; Degenring RF
    Klin Monbl Augenheilkd; 2003 Jun; 220(6):384-90. PubMed ID: 12830391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Update of intravitreal steroids for the treatment of diabetic macular edema.
    Bandello F; Preziosa C; Querques G; Lattanzio R
    Ophthalmic Res; 2014; 52(2):89-96. PubMed ID: 25195600
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Locally administered ocular corticosteroids: benefits and risks.
    McGhee CN; Dean S; Danesh-Meyer H
    Drug Saf; 2002; 25(1):33-55. PubMed ID: 11820911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.